AO Innovation Translation Center Clinical Science, AO Foundation, Davos, Switzerland.
Global Provider and Payer Value Demonstration, Global Health Economics, Johnson & Johnson Medical Devices, New Brunswick, NJ, USA.
Injury. 2024 Apr;55(4):111445. doi: 10.1016/j.injury.2024.111445. Epub 2024 Feb 20.
Recent clinical studies have shown favorable outcomes for cement augmentation for fixation of trochanteric fracture. We assessed the cost-utility of cement augmentation for fixation of closed unstable trochanteric fractures from the US payer's perspective.
The cost-utility model comprised a decision tree to simulate clinical events over 1 year after the index fixation surgery, and a Markov model to extrapolate clinical events over patients' lifetime, using a cohort of 1,000 patients with demographic and clinical characteristics similar to that of a published randomized controlled trial (age ≥75 years, 83 % female). Model outputs were discounted costs, quality-adjusted life years (QALYs), and incremental cost-effectiveness ratio (ICER) over a lifetime. Deterministic and probabilistic sensitivity analyses were performed to assess the impact of parameter uncertainty on results.
Fixation with augmentation reduced per-patient costs by $754.8 and had similar per-patient QALYs, compared to fixation without augmentation, resulting in an ICER of -$130,765/QALY. The ICER was most sensitive to the utility of revision surgery, mortality risk ratio after the second revision surgery, mortality risk ratio after successful index surgery, and mortality rate in the decision tree model. The probability that fixation with augmentation was cost-effective compared with no augmentation was 63.4 %, 58.2 %, and 56.4 %, given a maximum acceptable ceiling ratio of $50,000, $100,000, and $150,000 per QALY gained, respectively.
Fixation with cement augmentation was the dominant strategy, driven mainly by reduced costs. These results may support surgeons in evidence-based clinical decision making and may be informative for policy makers regarding coverage and reimbursement.
最近的临床研究表明,在固定转子间骨折时,使用骨水泥增强固定具有良好的效果。我们从美国支付者的角度评估了在闭合性不稳定转子间骨折固定中使用骨水泥增强固定的成本效果。
成本效果模型包括一个决策树,用于模拟指数固定手术后 1 年内的临床事件,以及一个马尔可夫模型,用于根据类似已发表的随机对照试验(年龄≥75 岁,83%为女性)的患者特征,外推患者终身的临床事件。模型输出为终生的贴现成本、质量调整生命年(QALY)和增量成本效果比(ICER)。进行了确定性和概率敏感性分析,以评估参数不确定性对结果的影响。
与不使用骨水泥增强固定相比,使用骨水泥增强固定可降低每位患者 754.8 美元的固定成本,且每位患者的 QALY 相似,因此 ICER 为-130765 美元/QALY。ICER 对翻修手术的效用、第二次翻修手术后的死亡率风险比、成功的指数手术后的死亡率风险比以及决策树模型中的死亡率最敏感。在给定最大可接受的上限比率为 50000 美元、100000 美元和 150000 美元/QALY 时,与不进行骨水泥增强固定相比,使用骨水泥增强固定具有成本效果的概率分别为 63.4%、58.2%和 56.4%。
使用骨水泥增强固定是主导策略,主要是因为成本降低。这些结果可能有助于外科医生进行基于证据的临床决策,并为政策制定者提供有关覆盖范围和报销的信息。